Cordyceps Sunshine Biotech Holdings Co., Ltd. (RAJAF)

Cordyceps Sunshine Biotech Holdings Co., Ltd. grows and sells cordyceps—a fungus used in traditional Chinese medicine—along with derivative supplement products. The company was incorporated in Taiwan in 2020 and trades on the OTC market under the symbol RAJAF. It is a small, specialized firm with operations centered in Taiwan and distribution channels reaching Hong Kong and mainland China.

What is cordyceps

To understand the company, you need to know what cordyceps actually is. Cordyceps is a genus of parasitic fungus that attacks insects and uses them as hosts. The most prized variety is Ophiocordyceps sinensis, which lives in high-altitude soil in the Himalayas and infects ghost moth caterpillars. When the fungus colonizes the caterpillar, it eventually kills it, and the fungus body emerges from the dead insect’s head. These desiccated cordyceps—caterpillar body plus fungus—have been harvested and used in traditional Chinese medicine for hundreds of years.

Genuine wild cordyceps are vanishingly rare and extremely expensive, sometimes selling for thousands of dollars per gram. Cordyceps Sunshine does not hunt for wild cordyceps. Instead, the company cultivates cordyceps in controlled environments. This is what allows the company to produce cordyceps at scale and at a price that consumers and retailers can actually afford.

The product line

Cordyceps Sunshine makes two main forms of cultivated cordyceps: dry cordyceps and fresh cordyceps. The dry form is what most people picture when they think of the product—shriveled fungi that look vaguely like small sticks and are brewed into tea or ground into powder. The fresh form is cordyceps grown on grain or other substrates and sold in a more shelf-stable state than truly fresh cordyceps, which would spoil quickly.

Beyond cordyceps alone, the company sells derivative products. The Taiwanofungus Oral Pill is a capsule containing cordyceps extract and other ingredients. Taiwanofungus Double A Oral Shot is a liquid supplement in shot form. The company also sells Taiwanofungus x Salvia Miltiorrhiza Oral Shot, which blends cordyceps with salvia, another plant used in traditional Chinese medicine. There is also Collagen Max Drink, a liquid supplement aimed at a different health claim than cordyceps—this one playing to consumer interest in skin and joint health.

All of these products are classified and sold as dietary supplements, not pharmaceuticals.

How it makes money

Revenue comes from selling cordyceps and cordyceps-based products to distributors, retail chains, and directly to consumers. The company uses multiple channels: it sells through major e-commerce platforms like Alibaba and local Chinese equivalents, through partnerships with physical chain stores and retailers across Taiwan and China, and through direct-to-consumer online sales.

The margins on these sales depend on the channel. Direct-to-consumer online sales carry the highest margin because the company keeps all the profit spread. Sales through major retail chains and e-commerce marketplaces mean lower margins because the retailer or platform takes a commission. The company’s cost of goods sold includes the cost of cultivating or sourcing cordyceps and manufacturing supplements, which are then sold at retail prices that consumers associate with a traditional Chinese medicinal product—not cheap, but substantially more affordable than wild cordyceps.

Distribution to Hong Kong and mainland China extends the addressable market beyond Taiwan’s 23 million people to hundreds of millions in the region who buy traditional health supplements.

A small and focused company

Cordyceps Sunshine is not a pharmaceutical giant. It is a niche company in the dietary supplement space. It has not undergone extensive clinical trials for cordyceps efficacy in the way a drug company must. The products are sold on the basis of traditional use and consumer belief in their health benefits—a segment that is real and substantial in Asia but small compared to mainstream pharmaceuticals or large supplement companies in the West.

The company’s strengths are in cultivation expertise, brand recognition within its niche, and the appeal of cordyceps as a product. Its main vulnerabilities are the small size of the overall business, dependence on retail trends in Asia, exposure to currency fluctuations in the Chinese yuan and Hong Kong dollar, and the risk that consumer preferences might shift away from traditional supplements toward other health products.

Competition and market position

Cordyceps is not a unique product category. Many other companies worldwide cultivate and sell cordyceps. The company competes in an undifferentiated market where multiple players sell similar products at similar prices. What sets a company apart is brand, distribution, pricing, and the specific formulations of derivative products. Cordyceps Sunshine has chosen to operate primarily in Taiwan and China, where traditional medicinal products have deep cultural roots and established consumer demand.

The market for cordyceps and traditional health supplements in Asia is mature and stable rather than fast-growing. Cordyceps is not a trending supplement the way collagen or turmeric became trendy in the West; it is an established category with a loyal base of consumers who have used it for decades. This means the company’s revenue is less likely to surge on a fad, but also less likely to collapse. It is a steady business in a steady category.

What investors would research

For anyone studying Cordyceps Sunshine, the key question is the company’s ability to grow revenue in a mature market. The 10-K filing (SEC CIK 0001885680) will show revenue by product line and by geography, if that detail is disclosed. The most important metrics are year-over-year sales growth, gross margin, and the health of the company’s retail relationships.

Because the company trades on the OTC market and is small, information is less abundant than for Nasdaq-listed companies. The annual report and quarterly filings are the best sources. An investor would want to understand what proportion of revenue comes from direct e-commerce versus retail partnerships, whether retail chains are increasing or decreasing their shelf space allocated to the brand, and whether the company is expanding into new product categories or consolidating around cordyceps-focused lines.

Cordyceps Sunshine is a straightforward business: it grows fungi, makes supplements, and sells them to people who believe in the health benefits. Whether that belief is well-founded is a question for medical research; whether the business is sound is a question about growth, margins, and customer retention—the ordinary questions any small company faces.